Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

被引：8

作者：

Yu, E. ^{[1
]}

Piulats, J. M. ^{[2
]}

Gravis, G. ^{[3
]}

Fong, P. C. C. ^{[4
]}

Todenhoefer, T. ^{[5
]}

Laguerre, B. ^{[6
]}

Arranz Arija, J. A. ^{[7
]}

Oudard, S. ^{[8
]}

Massard, C. ^{[9
,10
]}

Stoeckle, M. ^{[11
]}

Nordquist, L. T. ^{[12
]}

Carles, J. ^{[13
]}

Kolinsky, M. P. ^{[14
]}

Augustin, M. ^{[15
]}

Gurney, H. ^{[16
,17
]}

Tafreshi, A. ^{[18
]}

Li, X. T. ^{[19
]}

Poehlein, C. H. ^{[19
]}

Schloss, C. ^{[19
]}

de Bono, J. S. ^{[20
]}

机构：

[1] Univ Washington, Med Oncol, Seattle, WA 98195 USA

[2] Catalan Inst Oncol, Med Oncol, Barcelona, Spain

[3] Inst Paoli Calmettes, Med Oncol, Paris, France

[4] Auckland City Hosp, Med Oncol, Auckland, New Zealand

[5] Studienpraxis Urol, Urol, Nuertingen, Germany

[6] Ctr Eugene Marquis, Med Oncol, Rennes, France

[7] Gen Univ Hosp Gregorio Maranon, Med Oncol, Madrid, Spain

[8] Hop Europeen Georges Pompidou, Med Oncol, Paris, France

[9] Gustave Roussy Canc Campus, Med Oncol, Villejuif, France

[10] Paris Sud Univ, Villejuif, France

[11] Saarland Univ Hosp, Urol, Homburg, Germany

[12] Urol Canc Ctr, GU Res Network, Med Oncol, Omaha, NE USA

[13] Vall dHebron Univ Hosp, Genitourinary Oncol, Barcelona, Spain

[14] Cross Canc Inst, Med Oncol, Edmonton, AB, Canada

[15] Paracelsus Med Univ, Urol, Nurnberg, Germany

[16] Westmead Hosp, Med Oncol, Sydney, NSW, Australia

[17] Macquarie Univ Hosp, Sydney, NSW, Australia

[18] Univ Wollongong, Med Oncol, Wollongong, NSW, Australia

[19] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[20] Royal Marsden NHS Fdn Trust, Med Oncol, London, England

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1125

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

612P

引用

页码：S652 / S653

页数：2

共 50 条

[41] Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.
Massard, Christophe
Retz, Margitta
Hammerer, Peter
Quevedo, Fernando
Fong, Peter C. C.
Berry, William R.
Gurney, Howard
Piulats, Josep M.
Joshua, Anthony M.
Linch, Mark David
Kolinsky, Michael Paul
Romano, Emanuela
Sridhar, Srikala S.
Conter, Henry Jacob
Augustin, Marinela
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[42] Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921
Petrylak, Daniel Peter
Shore, Neal D.
Bennamoun, Mostefa
Ratta, Raffaele
Piulats, Josep M.
Li, Ben
Schloss, Charles
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[43] KEYNOTE-641: Phase III study of pembrolizumab (pembro) plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC)
Graff, J. N.
Burgents, J.
Liang, L. W.
Stenzl, A.
ANNALS OF ONCOLOGY, 2019, 30
[44] Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
Yu, Evan Y.
Berry, William R.
Gurney, Howard
Retz, Margitta
Conter, Henry J.
Laguerre, Brigitte
Fong, Peter C. C.
Ferrario, Cristiano
Todenhofer, Tilman
Gravis, Gwenaelle
Piulats, Josep M.
Emmenegger, Urban
Shore, Neal D.
Romano, Emanuela
Mourey, Loic
Li, Xin Tong
Poehlein, Christian H.
Schloss, Charles
Appleman, Leonard J.
Bono, Johann S. de
EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03): : 509 - 518
[45] Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.
Fong, Peter C. C.
Retz, Margitta
Drakaki, Alexandra
Massard, Christophe
Berry, William R.
Romano, Emanuela
De Bono, Johann S.
Feyerabend, Susan
Appleman, Leonard Joseph
Conter, Henry Jacob
Sridhar, Srikala S.
Shore, Neal D.
Linch, Mark David
Joshua, Anthony M.
Gurney, Howard
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[46] Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up.
Graff, Julie Nicole
Alumkal, Joshi J.
Thompson, Reid F.
Moran, Amy
Thomas, George V.
Wood, Mary A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[47] Clinical Activity of Enzalutamide in Docetaxel-Naive and Docetaxel-Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer
Nadal, Rosa
Zhang, Zhe
Rahman, Hibba
Schweizer, Michael T.
Denmeade, Samuel R.
Paller, Channing J.
Carducci, Michael A.
Eisenberger, Mario A.
Antonarakis, Emmanuel S.
PROSTATE, 2014, 74 (15): : 1560 - 1568
[48] Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
Yu, Evan Y.
Kolinsky, Michael P.
Berry, William R.
Retz, Margitta
Mourey, Loic
Piulats, Josep M.
Appleman, Leonard J.
Romano, Emanuela
Gravis, Gwenaelle
Gurney, Howard
Bogemann, Martin
Emmenegger, Urban
Joshua, Anthony M.
Linch, Mark
Sridhar, Srikala
Conter, Henry J.
Laguerre, Brigitte
Massard, Christophe
Li, Xin Tong
Schloss, Charles
Poehlein, Christian H.
de Bono, Johann S.
EUROPEAN UROLOGY, 2022, 82 (01) : 22 - 30
[49] PEMBROLIZUMAB plus LENVATINIB IN PATIENTS WITH ADENOCARCINOMA METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) OR TREATMENT-EMERGENT NEUROENDOCRINE MCRPC: PHASE 1B/2 KEYNOTE-365 COHORTS E/F
Kramer, Gero
Shore, Neal
Joshua, Anthony
Li, Xin Tong
Poehlein, Christian
Schloss, Charles
De Bono, Johann
Yu, Evan
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A449 - A449
[50] PEMBROLIZUMAB plus VIBOSTOLIMAB IN PATIENTS WITH ADENOCARCINOMA METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) OR TREATMENT-EMERGENT NEUROENDOCRINE MCRPC: PHASE 1B/2 KEYNOTE-365 COHORTS G/H
Shore, Neal
De Bono, Johann
Kramer, Gero
Joshua, Anthony
Li, Xin Tong
Poehlein, Christian
Schloss, Charles
Yu, Evan
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A455 - A455

← 1 2 3 4 5 →